Imaging scans with FLT to look for leukemia after treatment
Tests whether FLT scans can show leftover leukemia or myeloma after treatment.
Key facts
- Who runs it
- University of Oklahoma
- Where
- Atlanta, Oklahoma City, and Washington D.C., United StatesSee the 3 sites
- Trial code
- Registry title
- Pilot Imaging Study of Leukemia
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 60 people, planned
- Started
- 19 Jan 2023
- Expected to end
- Apr 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- FLT
- Record updated
- 23 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 4 to 80 with high-risk acute leukemia or myeloma that came back or did not respond to treatment. They will have 18F FLT imaging without sedation.
- Age
- 4 to 80 years
- Sex
- All sexes can join.
- Disease stage
- High-risk relapsed or refractory acute lymphocytic leukemia, acute myeloid leukemia, ambiguous lineage leukemia or myeloma.
- Earlier treatment
- Anticipated immunotherapy, or other non-immune treatment such as chemotherapy or radiotherapy not given for stem-cell transplant (HSCT).
Main reasons for not taking part
- Uncontrolled infection
- Pregnancy or breastfeeding
- Past allergy or intolerance to fluorothymidine
- Cannot have 18F FLT imaging without sedation
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 4 to 80 years
- Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma
- Karnofsky/Lansky score of ≥ 50
- Agree to use contraceptive measures during study protocol participation (when age appropriate)
- Patient or parent/guardian capable of providing informed consent
- Ability to undergo 18F FLT imaging without sedation
- Bilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal, Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher)
- Pulse oximetry of > 90% on room air
- Ability to undergo 18F FLT imaging without sedation
- Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy)
Who cannot take part
- History of prior fluorothymidine allergy or intolerance
- Patients with uncontrolled infections
- Pregnancy or lactating
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 80 years old?
Where in United States
- Emory UniversityAtlanta, United StatesContact: Kirsten M Williams, MDNot yet recruiting
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Jennifer Holter Chakrabarty, MDTaking people
- Children's National Health SystemWashington D.C., United StatesContact: Heme Onc Lead NurseNo longer taking part
About the trial
What the trial wants to find out
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
The 4 groups in the trial
- Standard therapy - Acute leukemia cohortExisting treatment, for comparison
The Arm will accrue patients receiving standard therapy from the high-risk acute leukemia cohort (18 patients).
Treatment: FLT
- Immunotherapy - Acute leukemia cohortTreatment being tested
The Arm will accrue patients receiving immunotherapy from the high-risk acute leukemia cohort (18 patients).
Treatment: FLT
- Standard therapy - Myeloma cohortExisting treatment, for comparison
The Arm will accrue patients receiving standard therapy from the myeloma cohort (9 patients).
Treatment: FLT
- Immunotherapy - Myeloma cohortTreatment being tested
The Arm will accrue patients receiving immunotherapy from the myeloma cohort (9 patients).
Treatment: FLT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging
- Plain-language title
- Imaging scans with FLT to look for leukemia after treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03633955, who can take part
- Record updated
- 23 April 2026